ABSTRACT Background: Nonalcoholic steatohepatitis (NASH) affects 3-5% of the general adult population and predisposes to cirrhosis, cardiovascular disease (CVD), and diabetes through unclear mechanisms. Lectin-like oxidized LDL receptor-1 (LOX-1) has been connected to CVD risk in the general population and to insulin resistance and hepatic fibrogenesis in experimental models. Objective: The objective was to assess the effect of the common functional LOX-1 IVS4-14 A/G polymorphism on liver disease, adipokines, oxidative stress, lipoprotein metabolism, and glucose homeostasis in NASH. Design: Forty nonobese, nondiabetic, normolipidemic biopsy-proven NASH patients and 40 age-, sex-, BMI-, and LOX-1 IVS4-14 A/G polymorphism-matched healthy control subjects underwent an oralfat-load test (OFT), with measurement of plasma triglyceride-rich lipoprotein (TRLP) subfractions, oxidized LDL, total antioxidant status (TAS), adipokines (resistin and adiponectin), and cytokeratin-18 fragments (marker of hepatocyte apoptosis). The subjects also underwent an oral-glucose-tolerance test (OGTT), with minimal model analysis to yield variables of glucose homeostasis. Results: The LOX-1 polymorphism was independently associated with liver histology (G allele carriers had more severe liver disease); during the OFT, the G allele was associated with small TRLP accumulation, lower TAS, adipokine imbalance (higher resistin and lower adiponectin), and increased cytokeratin-18 fragments. The G allele was also independently associated with insulin resistance, impaired pancreatic b cell function, and incretin effect during the OGTT. Conclusion: In NASH, the LOX-1 polymorphism is associated with liver disease severity and may predispose to CVD through modulation of postprandial small TRLPs and adipokine balance and to diabetes by affecting both insulin secretion and insulin sensitivity.
INTRODUCTION

NAFLD
4 is the most common chronic liver disease in the world, affecting 20-30% of the general adult population. It encompasses a histologic spectrum ranging from simple steatosis to steatosis plus necroinflammation (NASH), the latter having different severities of fibrosis. NASH is associated with an increased risk of developing cirrhosis/end-stage liver disease, diabetes, and CVD (1); the correlation of liver histology in NAFLD with the severity of early atherosclerosis and with the impairment in glucose metabolism suggests that the same molecular mechanisms may underlie liver injury, diabetes, and atherogenesis (1) . The knowledge of such mechanisms would help in selecting NASH subjects at greater risk of cardiometabolic and liver-related complications for early specific interventions and tight monitoring.
High circulating concentrations of oxidized LDLs are associated with an increased risk of metabolic disorders, including obesity, hyperglycemia, hypertriglyceridemia, and CVD (2) , with the putative mechanism being an increased cellular uptake of oxLDL, which triggers intracellular ROS production, cellular apoptosis, and inflammation. oxLDLs can also activate hepatic Kupffer and stellate cells and trigger inflammation and fibrogenesis (3, 4) . Consistently, increased oxLDL concentrations have been shown to correlate with histologic severity in liver tissue samples from NAFLD patients (5) .
LOX-1, a type II membrane protein belonging to the C-type lectin family, is a major scavenger receptor for oxLDL in endothelial cells and monocytes and is thought to play a key role in atherogenesis by triggering an oxLDL-induced inflammatory reaction in the vessel wall (6) . However, the widespread localization of oxLDL receptors in adipose tissue, pancreas, and liver suggests a role for this receptor in metabolic disorders. In animal models of high-fat diet-induced obesity, adipocyte LOX-1 expression is required for the secretion of proinflammatory cytokines and lipid-induced insulin resistance and the functional deletion of this receptor in adipose tissue blunts dietary fat-induced inflammatory response (7) . Consistently, adipose tissue LOX-1 expression correlates with proinflammatory adipokine expression and insulin resistance in nondiabetic humans (8) .
Finally, in mouse models of NAFLD, LOX-1 expression is a required step for activation of hepatic stellate cells and for the triggering of hepatic fibrogenesis (3) . Together, these data suggest that the functional regulation of LOX-1 activity may modulate not only atherogenesis in the vessel wall, but also adipose tissue inflammation and hepatic fibrogenesis.
Several LOX-1 functional SNPs have been recently linked to CVD susceptibility in humans (9) . The IVS4-14 A/G SNP is one of these functional SNPs: the A allele encodes a truncated LOX-1 splice isoform, named LOXIN, which lacks part of the extracellular domain, has a reduced binding capacity for oxLDLs, and blocks the cellular expression of the full-length LOX-1 receptors and their oxLDL binding activity (7) . As a consequence, LOXIN expression confers increased resistance to oxLDL-induced macrophage apoptosis and atherogenesis in vitro, and A allele carriers are protected, whereas homozygous G allele carriers are predisposed to CVD in vivo (10) . The effect of LOX-1 IVS4-14 A/G SNP on liver disease, glucose homeostasis, and lipoprotein metabolism is unknown. We hypothesized that LOX-1 IVS4-14 A/G SNP may modulate not only lipoprotein metabolism but also glucose metabolism, oxidative stress, inflammatory adipokine concentrations, and liver injury in NASH patients free of overt CVD, diabetes, or cirrhosis, which thereby explains the epidemiologic link between NASH, CVD, and diabetes.
SUBJECTS AND METHODS
On the basis of the available data, we considered a type I error of 0.05 and a type II error of 0.20: !12 subjects per arm were needed to detect a significant difference in liver histology and in glucose and lipoprotein metabolism variables (11, 12) . Of 96 patients referred by family physicians to our Hepato-Metabolic Clinic for chronic liver enzyme elevations since January 2008, 40 nonobese, nondiabetic, normolipidemic patients with biopsyproven NASH (13) without overt CVD were identified.
Subject selection
Besides histologic evidence, the diagnosis of NASH required that all of the following criteria be met: persistently (.6 mo) elevated liver enzymes, ultrasonographic bright liver without any other liver or biliary tract disease, negative viral markers, and a history of alcohol consumption ,20 g/d in men and ,10 g/d in women, as assessed by a detailed interview extended to family members and by a validated questionnaire completed daily for 1 wk by the patients.
The exclusion criteria were as follows: obesity [BMI (in kg/ m 2 ) !30], diabetes (fasting plasma glucose !126 mg/dL or plasma glucose !200 mg/dL at .2 h on OGTT or antidiabetic drugs), or overt dyslipidemia (fasting serum cholesterol !200 mg/dL or plasma triglyceride !200 mg/dL); exposure to occupational hepatotoxins or drugs known to be steatogenic, to be hepatotoxic, or to affect lipid or glucose metabolism; positive autoimmune or celiac disease markers; or abnormal copper metabolism, serum a 1 -antitripsin, or thyroid function. Mutations in the hemochromatosis genes HFE and TRF2 were detected in patients and control subjects by using a multiplex amplification reaction (Nuclear Laser Medicine). LIC and HII were assessed from 2 mg dry-weight tissue by atomic absorption spectroscopy.
Of 276 healthy subjects enrolled in a population-based cohort study, 40 healthy control subjects matched for LOX-1 genotype, age, sex, BMI, and waist circumference were randomly identified. To further rule out subclinical liver disease in control subjects, beside a negligible alcohol intake (,20 g/d in men and ,10 g/d in women) and normal abdomen ultrasound, the upper healthy ALT limit was lowered to ,30 U/L (males) and ,20 U/L (females) (14) . Patients and control subjects gave their consent to the study, which was conducted according to the Helsinki Declaration.
Genetic analyses
Patients and control subjects were genotyped for LOX-1 IVS4-14 A/G, MTP-493 G/ T, and ApoE polymorphisms (see the Supplemental material under "Supplemental data" in the online issue).
Alimentary record
Daily, the subjects completed a dietary record for 1 wk, according to the European Prospective Investigation into Cancer and Nutrition protocol, which was analyzed by using the WinFood database (Medimatica) as previously described (15, 16) .
Anthropometric measures
Percentage body fat was estimated by bioelectrical impedance analysis (TBF-202; Tanita), which closely correlated with dualenergy X-ray absorption (17) .
Cytokines
To assess the effect of LOX-1 IVS4-14 A/G SNP on adipose tissue-produced adipokines, we measured serum adiponectin, TNF-a, resistin, and leptin by immunoenzymatic methods (see the Supplemental material under "Supplemental data" in the online issue). Adiponectin and resistin, in particular, have been consistently linked to the severity of steatosis, necroinflammation, and fibrosis in NASH and to lipoprotein metabolism and were measured at each time of the OFT (18-21).
Hepatocyte apoptosis
Hepatocyte apoptosis characterizes liver injury and disease progression in NAFLD and is a distinctive feature of NASH (22) . Plasma ELISA-detected CK-18 fragments have been validated as an accurate marker of hepatic caspase-3-generated CK-18 fragments, hepatocyte apoptosis, and hepatic necroinflammation in NASH (1) . Plasma CK-18 fragments were measured at each time of the OFT in patients and control subjects (see the Supplemental material under "Supplemental data" in the online issue).
Nitrosative stress
Plasma nitrotyrosine was chosen as a marker of nitrosative stress, which is believed to play a crucial role in the pathogenesis of both cardiovascular complications in insulin-resistant conditions and liver injury in NASH (23) . Fasting plasma nitrotyrosine was measured by a commercial ELISA kit product by HyCult Biotechnology (Pantec).
OGTT-derived indexes of glucose homeostasis
After completion of the alimentary record, participants underwent a standard 75-g OGTT, with measurement of glucose, insulin, and C-peptide at every time point, and minimal model analysis was performed to yield indexes of glucose homeostasis (see the Supplemental material under "Supplemental data" in the online issue). Whole-body insulin sensitivity was estimated from a model of glucose clearance, which provides the OGIS, an index of whole-body insulin sensitivity, and the hepatic insulin resistance index was calculated from OGTT as previously proposed. Both of these indexes were validated against a clamp in nondiabetic subjects (24, 25) . The following indexes of b cell function were also calculated: the IGI and the CGI and the 2 integrated indexes of b cell function (DI and AI), which relate b cell insulin secretion to insulin resistance and represent integrated variables of b cell function. DI and AI were previously validated against FIVGTT minimal model variables in NAFLD and in nondiabetic subjects (10, 26) ; they also accurately predict the development of type 2 diabetes in the general population (27) .
Incretin effect
To assess whether differences in b cell function were related to a reduced incretin stimulatory effect on b cell, an FIVGTT was performed, and the incretin effect, ie, the effectiveness of ingested compared with intravenous glucose in stimulating b cell insulin secretion, was assessed (see the Supplemental material under "Supplemental data" in the online issue).
Oral fat load
Within 2 wk of the OGTTs, participants underwent an OFT, as previously detailed (9) . Blood samples were drawn every 2 h for 10 h, and the following variables were measured: 1) Plasma total cholesterol, triglyceride, and FFA concentrations were measured with automated enzymatic methods 2) TRLPs were isolated through preparative ultracentrifugation and subfractionated (see the Supplemental material under "Supplemental data" in the online issue) 3) Markers of oxidative stress (TAS and LDL conjugated dienes), cytokeratin-18 fragments, and adipokines (resistin and adiponectin).
Statistical analysis
Data were expressed as means 6 SEMs. Differences across groups were analyzed by ANOVA and then by followed by Bonferroni correction, when variables were normally distributed; otherwise the Kruskal-Wallis test, followed by the post hoc Dunn test, was used to compare nonparametric variables. Normality was evaluated by using the Shapiro-Wilk test. Fisher's or chi-square test were used to compare categorical variables, as appropriate.
The AUC and IAUC of variables measured during the OFT and the OGTT were computed by the trapezoid method. Multivariate repeated-measures ANOVA was used to test the interaction between time and group during the OFT. When a significant interaction was found between factors, differences across groups were analyzed by ANOVA followed by Bonferroni's correction if variables were normally distributed; otherwise, the KruskalWallis test was performed, followed by the post hoc Dunn test to compare nonparametric variables. Differences were considered significant at P , 0.05.
Analysis of dietary, anthropometric, and metabolic variables and of genetic polymorphisms was made by using a Spearman's correlation test. Genetic polymorphisms were modeled as an additive effect, ie, quantitative predictor variables reflecting the number of risk alleles (0, 1, or 2).When a relation was found on univariate analysis, multiple regression analyses were used to estimate the relation between different variables, after log transformation of skewed data. For liver histology, predictors of severe (.66% hepatocytes) steatosis, necroinflammatory grade 3, or fibrosis stage 3 were entered in a logistic regression analysis. Continuous variables were divided in quartiles On the basis of univariate analysis, the covariates were waist circumference; OGIS; fasting and postprandial adiponectin, resistin, and cytokeratin-18; IAUC-triglycerides and FFAs; MTP; and LOX-1 polymorphisms. STATISTICA software 5.1 (Statsoft Italia) was used.
RESULTS
Subjects characteristics
Main features of the patients and control subjects, grouped according to LOX-1 IVS4-14 A/G genotype, are reported in Table 1 . In patients and control subjects, the prevalence of the LOX-1 AA genotype was 34%, of the AG genotype was 33%, and of the homozygous GG genotype was 33%.
Patients with NASH had higher plasma nitrotyrosine and insulin and lower HDL cholesterol and adiponectin concentrations than did the control subjects. Systolic and diastolic blood pressures were higher in the NASH patients than in the control subjects, and they were higher in LOX-1 IVS4-14 G-allele carriers than in homozygous AA carriers within the patient and control groups. On the basis of Adult Treatment Panel III criteria for the definition of the metabolic syndrome, 22% of NASH patients and 8% of control subjects had the whole spectrum of the metabolic syndrome (P = 0.117).
The presence of the LOX-1 IVS4-14 G allele was associated with the severity of liver steatosis, necroinflammation, and fibrosis in NASH patients (Table 1) , whereas the LIC and HII were comparable across LOX-1 genotypes (data not shown).
Alimentary record
No differences were found in daily total energy, macro-and micronutrient, fat, and antioxidant vitamin intakes between patients with NASH and control subjects and between different LOX-1 genotypes (data not shown). Daily alcohol intake was similar in the 2 groups: 11 6 4 and 13 6 2 g (P = 0.979). Differences across groups were analyzed by ANOVA, followed by Bonferroni correction when variables were normally distributed; otherwise the Kruskal-Wallis test, followed by the post hoc Dunn test, was used to compare nonparametric variables. Normality was evaluated with the Shapiro-Wilk test. Fisher's or a chi-square test was used to compare categorical variables, as appropriate. Only significant Pinteractions were reported. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; C, cholesterol; GGT, c-glutamyl transferase; hs-CRP, highly sensitive C-reactive protein; IFG, impaired fasting glycemia; IGR, impaired glucose regulation; LOX-1, lectin-like oxidized LDL receptor-1; MetS, metabolic syndrome; MTP, microsomal triglyceride transfer protein; NASH, nonalcoholic steatohepatitis; WHR: waist-to-hip ratio. To convert mg/dL to mmol/L, multiply by 0.0555.
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To convert lU/mL to pmol/L, multiply by 6.945.
OGTT-derived indexes of glucose homeostasis
Minimal model indexes of glucose homeostasis are represented in Table 2 . As a group, NASH patients had a lower whole-body insulin sensitivity index (OGIS), higher hepatic insulin resistance, and lower b cell function indexes. In patients and control subjects, OGIS was reduced across LOX-1 IVS4-14 A/G genotypes (genotype AA . genotype AG . genotype GG), and the presence of the LOX-1 IVS4-14 G allele was associated with the severity of hepatic insulin resistance (genotype AA , genotype AG , genotype GG). In both groups, the b cell function indexes IGI, CGI, DI, and AI and the incretin effect were also reduced across LOX-1 IVS4-14 A/G genotypes in both patients and control subjects (genotype AA . genotype AG . genotype GG).
Oral-fat-tolerance test
ApoE genotype distribution did not differ between NASH patients and control subjects or across different LOX-1 IVS4-14 A/G genotypes. Postprandial plasma triglyceride, FFA, LDL conjugated diene, and VLDL1 subfraction responses of both intestinal and hepatic origin were higher in NASH patients than in control subjects, and plasma TAS and adiponectin rose postprandially in control subjects, whereas they fell in NASH patients (Table 3; Figure 1 ).
Within both patients and control subjects, the presence of the LOX-1 G allele was associated with a higher postprandial response in VLDL2 of both intestinal and hepatic origin, with a deeper decrease in adiponectin and TAS and with a more pronounced resistin increase (Table 3; Figure 1 ). Fasting and postprandial plasma CK-18 fragments were higher in NASH patients than in control subjects, and the G allele was associated with a higher postprandial plasma CK-18 response in patients and control subjects (Table 3 )
Correlative analysis
Main univariate correlations between anthropometric, metabolic, and dietary variables in NASH patients are shown elsewhere (see supplementary Table 1 under "Supplemental data" in the online issue). The results of multiple regression analysis are shown in Table 4 and Table 5 . The main determinants of severe liver histology in logistic regression analysis are reported in Table 6 .
DISCUSSION
The novel findings of our study are the following: 1) LOX-1 IVS4-14 A/G SNP is associated with the severity of liver disease in NASH 2) LOX-1 IVS4-14 A/G SNP also modulates insulin sensitivity and b cell function in NASH patients and healthy control subjects 3) LOX-1 IVS4-14 A/G SNP modulates postprandial small TRLP metabolism, plasma adipokines, and hepatocyte apoptosis markers after fat ingestion in NASH patients and healthy control subjects.
The first novel finding is the association of LOX-1 IVS4-14 A/G SNP with the severity of liver disease in NASH. LOX-1
TABLE 2
OGTT-derived indexes of glucose homeostasis in patients with nonalcoholic steatohepatitis and control subjects according to LOX-1 IVS4-14
Control subjects (n = 14)
Control subjects (n = 13)
Control subjects (n = 13) NASH (n = 13) 
P-main effect
P-group effect
P-interaction
OGIS (mL
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TABLE 3
Oral-fat-load variables of patients with NASH grouped according to LOX-1 IVS4-14
Control subjects (n = 13) NASH (n = 13)
P-main effect
P-main status
P-interaction
Fasting triglyceride (mg/dL) All values are means 6 SEMs. The AUCs and IAUCs of variables measured during the oral-fat-load and the oral-glucose-tolerance tests were computed by the trapezoid method. Multivariate repeatedmeasures ANOVA was used to test the interaction between time and group during the oral-fat-load test. When a significant interaction was found between factors, differences across groups were analyzed by ANOVA followed by Bonferroni's correction if variables were normally distributed; otherwise, the Kruskal-Wallis test was performed, followed by the post hoc Dunn test to compare nonparametric variables. Differences were considered significant at P , 0.05. Only significant P-interactions were reported. apo, apolipoprotein; CD, conjugated dienes; FFA, free fatty acid; IAUCs, incremental AUCs; LOX-1, lectinlike oxidized LDL receptor-1; NASH, nonalcoholic steatohepatitis; TAS, total antioxidant status.
SNP remained independently associated with severe liver histology after adjustment for adipokines and other confounders (Table 6 ), which suggests that LOX-1 function may directly modulate liver disease progression in NASH. Several experimental data are consistent with our findings: hepatic expression of LOX-1 receptor-enhanced oxLDL uptake and oxidative stress in the liver of apolipoprotein E-deficient mice (28) , and the LOX-1 receptor has been shown to mediate oxLDL-induced activation and fibrogenesis in cultured hepatic stellate cells, which supports the association of LOX-1 with histologic fibrosis in our patients (4). Furthermore, oxLDLs can also be taken up by hepatic Kupffer cells through scavenger receptors, triggering ROS production and recruiting circulating monocytes into the liver (23); consistently, a role of oxLDL-induced Kupffer cell activation in the pathogenesis of high fat-induced steatohepatitis was recently proposed (29) . Finally, steatosis may result from increased hepatic ROS production, a condition that impairs triglyceride oxidation and secretion (21) .
LOX-1 may also promote liver disease indirectly, through modulation of pro-and antiinflammatory adipokines (Tables 5  and 6 ), which play a key role in the pathogenesis of liver injury in NASH (15) (16) (17) (18) (19) . In particular, an enhanced LOX-1-mediated adipocyte uptake of circulating oxLDLs may impair the secretion of the antioxidant, antiinflammatory adipokine adiponectin and enhance secretion of proinflammatory cytokines, such as resistin (3) (4) (5) . Remarkably, the analysis of postprandial adiponectin, resistin, and cytokeratin-18 fragment responses supports a crucial role for LOX-1 in mediating a high-fat diet-induced inflammation and liver injury (4, 30) . Despite comparable fasting adipokine concentrations, the presence of the G allele induced a proinflammatory cytokine pattern postprandially, consisting of lower adiponectin and higher resistin concentrations.
LOX-1 IVS4-14 A/G SNP was also associated with insulin resistance and b cell dysfunction-determinants of the risk of developing type 2 diabetes. Recent epidemiologic data support the link between oxLDL and adverse glycometabolic outcomes and ng/mL for adiponectin and resistin (E-F). The AUC and incremental AUC of the variables measured during the OFT and the OGTT were computed by the trapezoid method. Multivariate repeated-measures ANOVA was used to test the interaction between time and group during the OFT. When a significant interaction was found between factors, differences across groups were analyzed by ANOVA followed by Bonferroni's correction if variables were normally distributed; otherwise, the Kruskal-Wallis test was performed, followed by the post hoc Dunn test to compare nonparametric variables. Differences were considered significant at P , 0.05. apo, apolipoprotein; LOX-1, lectin-like oxidized LDL receptor-1; NASH, nonalcoholic steatohepatitis; OFT, oral-fat-load test; OGTT, oral-glucose-tolerance test; SNP, single-nucleotide polymorphism; TAS, total antioxidant status; TG, triglycerides. (2, 31) . Circulating oxLDL concentrations and the degree of LOX-1 expression in adipose tissue have also been connected to the severity of adipose tissue inflammation and insulin resistance (5, 32) , and co-incubation of isolated human islet cells with oxLDLs triggered pancreatic b cell apoptosis and impaired insulin secretion through the c-Jun N-terminal kinase activation pathway (33, 34) . The independent association of LOX-1 IVS4-14 A/G SNP with b cell function and insulin resistance suggests that a more effective oxLDL internalization by LOX-1 in G allele carriers may impair glucose metabolism, regardless of circulating oxLDL concentrations. These findings need to be confirmed by further prospective, adequately powered cohort studies.
The effect of LOX-1 IVS4-14 A/G SNP on lipoprotein subfraction metabolism after fat ingestion in humans is also unknown. In our subjects, the G allele was associated with postprandial small TRLP accumulation. Because small TRLPs are represented by the atherogenic remnants, this may be a novel mechanism connecting LOX-1 polymorphism to CVD risk. Several potential mechanisms may link LOX-1 polymorphism to small TRLP accumulation: it was previously shown that remnant particles are ligands for LOX-1 receptor and can thereby induce the production of ROS and proinflammatory cytokines by endothelial cells and migration of vascular smooth muscle cells (35, 36) . It can therefore be speculated that the higher affinity for oxLDLs of LOX-1 receptor form encoded by the G allele may lead to preferential uptake of oxLDLs and delay clearance of 1 Genetic polymorphisms were modeled as an additive effect, ie, quantitative predictor variables reflecting the number of risk alleles (0, 1, or 2). For example, LOX-1-14 A/G SNP was coded as follows in the multiple regression analysis: AA = 0, AG = 1, and GG = 2. Multiple regression analysis was used to estimate relation between different variables, when an association was found on univariate analysis, after log transformation of skewed data. Only variables significantly associated with outcome variables are shown. IAUC, incremental AUC; IGI, insulinogenic index (Di30/Dg30); LOX-1, lectin-like oxidized LDL receptor-1; NASH, nonalcoholic steatohepatitis; OGIS, oral glucose insulin sensitivity index; OGTT, oral-glucose-tolerance test; SNP, single-nucleotide polymorphism; TAS, total antioxidant status. 1 Genetic polymorphisms were modeled as an additive effect, ie, quantitative predictor variables reflecting the number of risk alleles (0, 1, or 2). For example, LOX-1-14 A/G SNP was coded as follows in the multiple regression analysis: AA = 0, AG = 1, and GG = 2. Multiple regression analysis was used to estimate relation between different variables, when an association was found on univariate analysis, after log transformation of skewed data. Only variables significantly associated with outcome variables are shown. apo, apolipoprotein; IAUC, incremental AUC; LOX-1, lectin-like oxidized LDL receptor-1; NASH, nonalcoholic steatohepatitis; SNP, single-nucleotide polymorphism; TAS, total antioxidant status.
TABLE 6
Multiple logistic regression analysis for factors associated with severe (involving .60% hepatocytes) steatosis, necroinflammatory grade 3, and fibrosis stage 3, respectively, in patients with NASH (n = 40) 1 Predictors of severe (.66% hepatocytes) steatosis, necroinflammatory grade 3, or fibrosis stage 3 were entered in a logistic regression analysis. Continuous variables were divided into quartiles. Genetic polymorphisms were modeled as an additive effect, ie, quantitative predictor variables reflecting the number of risk alleles (0, 1, or 2). For example, LOX-1-14 A/G SNP was coded as follows in the logistic regression analysis: AA = 0, AG = 1, and GG = 2. On the basis of univariate analysis, the covariates were waist circumference; oral glucose insulin sensitivity index; fasting and postprandial adiponectin, resistin, and cytokeratin-18; IAUC-triglycerides and free fatty acids; microsomal triglyceride transfer protein; and LOX-1 polymorphisms. Only parameters significantly associated with outcome variables are shown. IAUC, incremental AUC; LOX-1, lectin-like oxidized LDL receptor-1; NASH, nonalcoholic steatohepatitis; SNP, single-nucleotide polymorphism.
TRLP remnants or, alternatively, that the increased uptake of oxLDLs by the liver may enhance hepatic secretion of small VLDL particles, which compete with chylomicron remnants for their clearance postprandially. This results in small TRLP accumulation. Clearly, further in vitro and in vivo kinetic studies need to clarify the functional pathways connecting LOX-1 A/G polymorphism to TRLP lipoprotein metabolism.
In conclusion, we provided evidence that LOX-1 IVS4-14 A/G SNP may be the connection between liver injury, diabetes, and CVD in NASH. Further in vitro and adequately powered prospective studies need to elucidate underlying mechanisms and to assess the usefulness of LOX-1 IVS4-14 A/G SNP for screening and treatment of patients at higher liver-related, metabolic, and CVD risk.
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